Insulet Corp Stock Price, News & Analysis

Bigfoot Biomedical has appointed Matt Rainville as Chief Commercial Officer, aiming to enhance the Bigfoot Unity® Diabetes Management Program. With over 20 years in healthcare commercialization, including roles at Insulet and Eli Lilly, Rainville will focus on expanding access to diabetes management solutions. CEO Jeffrey Brewer emphasized that this hiring is crucial as they seek to grow their presence in the market for insulin management. Rainville's leadership is expected to drive adoption of their innovative solutions for diabetes care.

Insulet Corporation announces leadership changes with Jim Hollingshead succeeding Shacey Petrovic as President and CEO, effective June 1, 2022. Petrovic steps down for personal family reasons but will remain on the Board and serve as an advisor until May 2023. Under Petrovic's leadership since January 2019, Insulet achieved revenue exceeding $1 billion in 2021, reflecting consistent growth. The company anticipates revenue growth of 12% to 16% for 2022, driven by its Omnipod product line, despite facing macroeconomic and inflationary pressures.

Insulet Corporation (NASDAQ: PODD) reported a strong financial performance for Q1 2022, with revenue of $295.4 million, a 17.1% increase year-over-year. Total Omnipod revenue rose 15.6% to $269.5 million. Operating income improved to $37.9 million, a significant rise from $16.3 million last year. The company also achieved a gross margin of 71.0%. For 2022, Insulet reaffirms revenue growth guidance of 12% to 16%, while addressing inflationary pressures affecting operating margins.

Insulet Corporation (NASDAQ: PODD) presented studies on its Omnipod 5 Automated Insulin Delivery System for type 2 diabetes at the ATTD conference in Barcelona. Results showed a significant average HbA1c reduction of 1.3% and a 31.4% decrease in insulin use among participants. User satisfaction was high, with a System Usability Scale score of 90.5. Additionally, data on type 1 diabetes outcomes were shared, with five presentations scheduled. Insulet aims to broaden access to the Omnipod 5, currently cleared for type 1 diabetes management in the U.S.

Insulet Corporation (NASDAQ: PODD) announces its financial results for Q1 2022 will be released on May 5, 2022, after market close. A conference call will follow at 4:30 p.m. Eastern Time. Insulet, a leader in tubeless insulin pump technology, provides innovative solutions for diabetes management through its Omnipod products. The Company aims to simplify insulin delivery with its unique and wearable Pod design, which operates for up to three days. The latest product is the Omnipod® 5, an automated system integrated with continuous glucose monitoring.

Insulet Corporation (NASDAQ: PODD) reported financial results for 2021, achieving over $1 billion in annual revenue for the first time, reflecting a 21.5% increase from the prior year. The Omnipod product line generated $1.0 billion in revenue, with U.S. sales rising 23.6%. The company recorded an operating income of $126 million and a net income of $16.8 million. The recent clearance of the Omnipod 5 automated insulin delivery system by the U.S. FDA is a notable achievement. For 2022, Insulet expects revenue growth between 12% to 16% and a 100 basis point increase in operating margins.

Insulet Corporation (NASDAQ: PODD) launches a unique initiative integrating diabetes representation into the video game Animal Crossing: New Horizons. Players can download designs for insulin pump outfits and access Omnipod Bay, a themed island promoting diabetes awareness through playful activities. A recent survey revealed that 94% of people with type 1 diabetes value cultural representation, yet 51% feel underrepresented. The launch event takes place today at 3:00 PM ET, featuring content creators raising funds for JDRF, with Insulet matching donations.

Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, will present at two investor conferences in March 2022. The first is the Raymond James 43rd Annual Institutional Investors Conference on March 7 at 1:05 PM ET, followed by the Cowen 42nd Annual Health Care Conference on March 8 at 9:50 AM ET. Live webcasts will be available on their website, along with replays post-event. Insulet aims to simplify insulin delivery with its innovative Omnipod system.